medigraphic.com
Instituto Nacional de Salud Pública

2020, Number 3

<< Back Next >>

salud publica mex 2020; 62 (3)

Reduction of HBV and HDV infection in two indigenous peoples of Peruvian Amazon after the vaccination against hepatitis B

Cabezas C, Trujillo O, Balbuena J, Terrazas M, Manrique-de Lara C, Marín L, Ramírez-Soto MC

Language: Spanish
References: 22
Page: 237-245
PDF size: 454.05 Kb.


ABSTRACT

Objective. To determine the outcome of the vaccination against hepatitis, we determined the prevalence of hepatitis B virus (HBV) and hepatitis D virus (HDV) infections, eight years after introduction of the vaccination. Materials and methods. A cross-sectional study was performed in 2 944 participants of 67 Kandozi and Chapra indigenous peoples in April 2010. Serological screening for hepatitis B surface antigen (HBsAg), antibody anti-HBc IgM and IgG, antibody anti-HBs and anti-HDV were determined by ELISA tests. Results. The prevalence rates of HBsAg, anti-HBc total, anti- HBs ≥10 mlUI/ml and anti-HDV were 2.3, 39.13, 50.95 and 2.11%, respectively. The prevalence rate of HBsAg in children ‹11 years was 0%. Among carriers of HBsAg, the prevalence rates of HDV and acute HBV infections were 2.11% (all were ›14 years) and 11.94%, respectively. HBsAg and anti-HBc total were associated with individuals ≥10 years (p‹0.001). Conclusions. These findings show the elimination of HBV carriers in children ‹11 years, eight years following introduction of the vaccination against HBV.


REFERENCES

  1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546-55. https://doi.org/10.1016/S0140- 6736(15)61412-X

  2. Bensabath G, Hadler SC, Soares MC, Fields H, Dias LB, Popper H, et al. Hepatitis delta virus infection and Labrea hepatitis. Prevalence and role in fulminant hepatitis in the Amazon Basin. JAMA. 1987;258(4):479-83.

  3. Cabezas C, Suárez M, Romero G, Carrillo C, García M, Reátegui J, et al. Hiperendemicidad de hepatitis viral B y Delta en pueblos indígenas de la Amazonía peruana. Rev Peru Med Exp Salud Publica. 2006;23(2):114-22.

  4. Garcia D, Porras A, Rico Mendoza A. Hepatitis B infection control in Colombian Amazon after 15 years of hepatitis B vaccination. Effectiveness of birth dose and current prevalence. Vaccine. 2018;36(19):2721-6. https:// doi.org/10.1016/j.vaccine.2017.11.004

  5. Cabezas C, Trujillo O, Zavaleta C, Culqui D, Suarez M, Cueva N, et al. Prevalencia de la infección por el virus de hepatitis B en niños menores de 5 años de comunidades indígenas de la Amazonía peruana posterior a intervenciones mediante inmunización. Rev Peru Med Exp Salud Publica. 2014;31(2):204-10.

  6. Ramírez-Soto MC, Ortega-Cáceres G, Cabezas C. Trends in mortality burden of hepatocellular carcinoma, cirrhosis, and fulminant hepatitis before and after roll-out of the first pilot vaccination program against hepatitis B in Peru: An analysis of death certificate data. Vaccine. 2017;35(31):3808-12. https://doi.org/10.1016/j.vaccine.2017.05.086

  7. Marceliano-Nunes H, de Cassia Costa Monteiro MR, Pereira-Soares MC. Prevalence of hepatitis B and D serological markers in the Parakanã, Apyterewa Indian Reservation, Pará State, Brazil. Cad Saude Publica. 2007;23(11):2756-66.

  8. Contreras-Pulache H, Pérez-Campos P, Huapaya-Huertas O, Chacón- Torrico H, Champin-Mimbel D, Freyre-Adrianzén L, et al. La salud en las comunidades nativas amazónicas del Perú. Rev Peru epidemiol. 2014;18(1):e10.

  9. Hagan OCK, Nsiah P, Obiri-Yeboah D, Yirdong F, Annan I, Eliason S, et al. Impact of universal childhood vaccination against hepatitis B in Ghana: A pilot study. J Public Health Afr. 2018;9(2):721. https://doi.org/10.4081/ jphia.2018.721

  10. Ministerio de Salud. La hepatitis B en el Perú [Internet]. Lima: MINSA, c2014 [citado noviembre 23, 2018]. Disponible en: http://www.minsa.gob.pe/ redtupacamaru/hepatitisb/informacion/hepatistisb_peru.html

  11. Fondo de las Naciones Unidas para la Infancia. Kandozi y Shapra frente a la hepatitis B. El retorno de lo visible. Lima: UNICEF, 2005.

  12. Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis. 2012;16(2):e82-8. https://doi.org/10.1016/j.ijid.2011.10.009

  13. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001;135(9):796- 800. https://doi.org/10.7326/0003-4819-135-9-200111060-00009

  14. Posuwan N, Wanlapakorn N, Sa-nguanmoo P, Wasitthankasem R, Vichaiwattana P, Klinfueng S, et al. The success of a universal hepatitis B immunization program as part of Thailand’s EPI after 22 Years’ Implementation. PLoS ONE. 2016;11(3):e0150499. https://doi.org/10.1371/journal. pone.0150499

  15. Rots NY, Wijmenga-Monsuur AJ, Luytjes W, Kaaijk P, de Graaf TW, van der Zeijst BA, et al. Hepatitis B vaccination strategies tailored to different endemicity levels: some considerations. Vaccine. 2010;28(4):893-900. https://doi.org/10.1016/j.vaccine.2009.10.125

  16. Fiestas-Solórzano V, Gonzáles-Noriega M, Fiestas F, Cabezudo E, Suárez M, Suárez V. Evaluación de la seroprotección contra sarampión, rubéola y hepatitis B en niños menores de cinco años del Perú, 2011. Rev Peru Med Exp Salud Publica. 2012;29(4):437-43.

  17. Zaffina S, Marcellini V, Santoro AP, Scarsella M, Camisa V, Vinci MR, et al. Repeated vaccinations do not improve specific immune defenses against Hepatitis B in non-responder health care workers. Vaccine. 2014;32(51):6902-10. https://doi.org/10.1016/j.vaccine.2014.10.066

  18. Davis LG, Weber DJ, Lemon SM. Horizontal transmision of hepatitis B virus. Lancet. 1989;1(8643):889-93. https://doi.org/10.1016/S0140- 6736(89)92876-6

  19. Yacoubi L, Brichler S, Mansour W, Le Gal F, Hammami W, Sadraoui A, et al. Molecular epidemiology of hepatitis B and Delta virus strains that spread in the Mediterranean North East Coast of Tunisia. J Clin Virol. 2015;72:126-32. https://doi.org/10.1016/j.jcv.2015.10.002

  20. di Filippo D, Cortes-Mancera F, Payares E. Montes N, de la Hoz F, Arbelaez MP, et al. Hepatitis D virus and hepatitis B virus infection in Amerindian communities of the Amazonas state, Colombia. Virol J. 2015;12(1):172-82. https://doi.org/10.1186/s12985-015-0402-5

  21. Sanou AM, Benkiraneb K, Tintoc B, Cissé A, Sagna T, Ilboudo AK, et al. Prevalence of Hepatitis B virus and Hepatitis D virus coinfection in Western Burkina Faso and molecular characterization of the detected virus strains. Int J Infect Dis. 2018;70:15-9. https://doi.org/10.1016/j. ijid.2018.02.004

  22. Fattowich G. Natural history and prognosis of hepatitis B sem. Liver Dis. 2003;23:47-58.




2020     |     www.medigraphic.com